GSK acquires ‘potential best-in-class’ medicine efimosfermin
GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to buy steatotic liver disease medication efimosfermin alfa.
The London-based pharmaceutical company said efimosfermin, Boston...
Wed, 14/05/2025 - 09:13